Biotech · Private company
SecuraBio
Track this companyFree. Adds SecuraBio to your Dealase workspace and tells you when its record changes.
Clinical trials222 recruiting or active
Pipeline programs29From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline29
- BendamustinePhase 3 · Indolent Non-Hodgkin's LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 3 · Indolent Non-Hodgkin's LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IPI-145Phase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- OfatumumabPhase 3 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 3 · Indolent Non-Hodgkin's LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 2 · Indolent Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 2 · CD20+ Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 2 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 2 · Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 2 · Peripheral T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 2 · CD20+ Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- PrednisonePhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- R-CHOPPhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 2 · CD20+ Follicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- DuvelisibPhase 1 · Mycosis FungoidesClinicalTrials.gov · fetched Nov 12, 2026
- IPI-145Phase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- IPI-145Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- IPI-145 (duvelisib)Phase 1 · Lymphocytic Leukemia, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- IPI-145 (duvelisib)Phase 1 · Hematologic MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- IPI-145 (duvelisib)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- ObinutuzumabPhase 1 · Lymphocytic Leukemia, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- RifampinPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- duvelisibLymphoma, Small LymphocyticClinicalTrials.gov · fetched Nov 12, 2026
- PI3K inhibitorLymphoma, Small LymphocyticClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials22
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesPHASE1 · NOT_YET_RECRUITING · started Jan 1, 2027ClinicalTrials.gov NCT07714187 · fetched Nov 12, 2026
- Duvelisib Following Chimeric Antigen Receptor T-Cell TherapyPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 28, 2022ClinicalTrials.gov NCT05044039 · fetched Nov 12, 2026
- Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell LymphomasPHASE2 · TERMINATED · started Jul 23, 2020ClinicalTrials.gov NCT04331119 · fetched Nov 12, 2026
- A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerPHASE1_PHASE2 · TERMINATED · started Jun 1, 2020ClinicalTrials.gov NCT04193293 · fetched Nov 12, 2026
- Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLTERMINATED · started Apr 23, 2020ClinicalTrials.gov NCT04342117 · fetched Nov 12, 2026
- A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaPHASE2 · COMPLETED · started Sep 24, 2019ClinicalTrials.gov NCT04038359 · fetched Nov 12, 2026
- A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)PHASE2 · COMPLETED · started Feb 22, 2018ClinicalTrials.gov NCT03372057 · fetched Nov 12, 2026
- Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaPHASE2 · WITHDRAWN · started Feb 12, 2018ClinicalTrials.gov NCT03370185 · fetched Nov 12, 2026
- Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPHASE2 · TERMINATED · started Feb 8, 2018ClinicalTrials.gov NCT03256045 · fetched Nov 12, 2026
- A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)PHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02711852 · fetched Nov 12, 2026
- Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)PHASE2 · WITHDRAWN · started Dec 1, 2015ClinicalTrials.gov NCT02605694 · fetched Nov 12, 2026
- A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)PHASE3 · WITHDRAWN · started Dec 1, 2015ClinicalTrials.gov NCT02576275 · fetched Nov 12, 2026
- Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)PHASE1 · TERMINATED · started Feb 1, 2015ClinicalTrials.gov NCT02292225 · fetched Nov 12, 2026
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)PHASE1_PHASE2 · TERMINATED · started Dec 1, 2014ClinicalTrials.gov NCT02391545 · fetched Nov 12, 2026
- Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145PHASE1 · COMPLETED · started Nov 1, 2014ClinicalTrials.gov NCT02307461 · fetched Nov 12, 2026
- Duvelisib in Hepatically Impaired Subjects Compared to Healthy SubjectsPHASE1 · COMPLETED · started Mar 1, 2014ClinicalTrials.gov NCT02095587 · fetched Nov 12, 2026
- A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07PHASE3 · COMPLETED · started Dec 1, 2013ClinicalTrials.gov NCT02049515 · fetched Nov 12, 2026
- A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)PHASE3 · COMPLETED · started Nov 1, 2013ClinicalTrials.gov NCT02004522 · fetched Nov 12, 2026
- Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145PHASE1 · COMPLETED · started Oct 1, 2013ClinicalTrials.gov NCT01947777 · fetched Nov 12, 2026
- Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of MidazolamPHASE1 · COMPLETED · started Aug 1, 2013ClinicalTrials.gov NCT01925911 · fetched Nov 12, 2026
- A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaPHASE2 · COMPLETED · started Jun 17, 2013ClinicalTrials.gov NCT01882803 · fetched Nov 12, 2026
- A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic MalignanciesPHASE1 · TERMINATED · started Oct 1, 2011ClinicalTrials.gov NCT01476657 · fetched Nov 12, 2026